Viridian Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
53.6%projected annual EPS growth
Analyst Coverage
16analysts covering
FY EPS (est.)
-$3.95next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| VRDN-008 Phase 1 Healthy Volunteer Data Readout | 31 Dec 2026 |
| TSHR Program IND Submission | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Veligrotug FDA PDUFA Decision QuarterlyTarget: FDA Approval Decision
Elegrobart (VRDN-003) BLA Submission Timeline QuarterlyTarget: BLA Submission in Q1 2027
Cash Runway and Liquidity Quarterly762.2MTarget: Fund operations through key clinical readouts into 2027
VRDN-008 Phase 1 Healthy Volunteer Data QuarterlyTarget: Data readout in 2H 2026
Watch Items
- Veligrotug PDUFA Target Action DateTrigger: June 30, 2026Action: Monitor FDA decision and prepare for immediate commercial launch if approved.
- TSHR Program IND SubmissionTrigger: Q4 2026Action: Track IND filing progress for the half-life extended anti-TSHR monoclonal antibody.
- Elegrobart (VRDN-003) BLA Filing PreparationTrigger: Q1 2027Action: Ensure clinical data package from REVEAL-1 and REVEAL-2 is compiled for submission.
Research as of 19 Jun 2026